Diaceutics PLC 42.9% potential upside indicated by Canaccord Genuity

Diaceutics PLC with ticker (LON:DXRX) now has a potential upside of 42.9% according to Canaccord Genuity.



Canaccord Genuity set a target price of 150 GBX for the company, which when compared to the Diaceutics PLC share price of 105 GBX at opening today (07/09/2023) indicates a potential upside of 42.9%. Trading has ranged between 74 (52 week low) and 118 (52 week high) with an average of 39,443 shares exchanging hands daily. The market capitalisation at the time of writing is £87,006,602.

Diaceutics PLC is a United Kingdom-based technology and solutions provider to the pharmaceutical industry. The principal activities of the Company and its subsidiaries are data, data analytics and implementation services. The Company offers a core suite of products and outsourced advisory services, which helps its pharma customers to optimize and deliver their marketing and implementation strategies for companion diagnostics. Its DRDX Data Solutions include Physician Mapping, Lab Mapping, DXRX Signal AND DXRX Disease Testing Rate Tracker. Its Tech Enabled Services include DXRX Lab Report Optimization, DXRX Lab Quality Assessment, DXRX Education, DXRX Advisory Board, DXRX Lab Alerts and DXRX for Labs. Its DXRX-The Diagnostic Network is a diagnostic commercialization platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.